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Higher level of IDO found in seropositive
leprosy subjects of our study supported
the results of previous studies which
indicate a high IDO protein expression in
lepromatous skin lesions and high IDO
activity in the sera of lepromatous leprosy
patients. People who live together under
one and the same roof with leprosy
patients with seropositive anti-PGL-I
antibody have higher risk for developing
leprosy (particularly the lepromatous
type) compared to those who have
contact with seronegative patients.
In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect
immune response and ultimately affecting further course of the disease
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 Introduction  
 
Leprosy still remains a major public health problem in Indonesia since the incidence of 
leprosy is relatively high.1 It is possibly due to contact with seropositive leprosy patients 
that have been turning into manifest leprosy.  
Measuring the level of anti-phenolic glycolipid-1 immunoglobulin M (PGL-1 IgM) is one 
of the methods to detect seropositive leprosy subjects.2,3 The level of such cellular 
immune response will determine leprosy spectrum. The cellular immunity in leprosy 
tuberculoid type is still good, on the contrary, there is decreased cellular immunity in 
leprosy lepromatous type.4 Individuals with seropositive leprosy contact (IgM anti-PGL-
1 level more than 600 unit/ml), have a tendency to experience a change into leprosy 
lepromatous type.  
Previous studies have demonstrated that leprosy patients with lepromatous type have a 
higher activity of indoleamine 2, 3-dioxygenase (IDO) compared to those with 
tuberculoid type. The role of IDO levels in leprosy has been studied and an increased 
number of macrophages/dendritic cells (DC–lineage IDO+ cells were found in 
lepromatous (LL) compared to tuberculoid (BT) and reversal reaction massive 
macrophage infiltration containing a variable number of Virchow cells, full of bacilli 
accompanied by few lymphocytes, separated from the flat epidermis by a clear zone. BT 
lesions were characterized by an organized dermal granuloma composed of phagocytic 
cells with evident epithelioid differentiation surrounded by lymphocytes of giant cells. 
RR lesions showed activated macrophages with an epithelioid appearance, organized or 
not as granuloma.5  
However, no study has been conducted to evaluate how IDO level can be correlated to 
seropositive leprosy subjects (IgM anti PGL – 1 level more than 600 unit/ml) and have 
not showed a clinical manifestation on the skin. Our study aimed to identify the difference 
of IDO level between seropositive and seronegative leprosy subjects. 
  
Methods  
 
Our study was an observational study using a cross-sectional method. In August 2015, 
the study was conducted in Brebes, Central Java, Indonesia. Ethical clearance was 
approved by the Ethics Committee of Medical and Public Health Research, Faculty of 
Public Health, Diponegoro University.  
The eligible subjects participated in our study were those who fulfilled the inclusion 
criteria: individuals who were living together with a leprosy patient, age between 15-55 
years, showed no clinical symptom of leprosy, were not taking immunosuppressants 
during the last three months prior to the study and those who were willing to participate 
in our study. They also did not suffer from tuberculosis and did not take any anti-
tuberculosis medications. The subjects were divided into 2 groups, i.e. those with 
seropositive leprosy (anti PGL-1 IgM > 600 unit/mL) 6 and those who were seronegative.  
Five milliliters of venous blood was drawn from each subject. The whole blood was 
centrifuged to separate the serum, which was then stored at – 70°C. Seropositive leprosy 
was determined by measuring the levels of anti-PGL-1 IgM antibodies using enzyme-
linked immunosorbent assay (ELISA) (Polyclonal rabbit anti-human IgM/HRP (Dako ®) 
and analyzing IDO levels using ELISA commercial kits (Cusabio®, Catalog No: CSB-
E09966h). All tests were conducted at the Institute Tropical Disease Laboratory, 
Airlangga University, Surabaya.  
The education level of subjects was categorized into 2 groups, i.e. basic and moderate 
education. Subjects in basic education group were those who had completed their 
elementary and junior high school; while moderate education group involved those with 
senior high school educational background  
 
Results  
 
Table 1 shows that the gender, level of education and age had no effect on the 
seropositivity (anti-PGL-1 IgM antibodies levels) in leprosy patients; but the levels of IDO 
were significantly different between seropositive leprosy with seronegative subjects (p = 
0.048).  
In sex variable, there were 20.7% male and 79.3% female with seropositive leprosy and 
33.3% male and 66.7% female with seronegative leprosy. There is no significant 
difference between seropositive leprosy subjects and seronegative leprosy subjects in 
sex variable (p = 0.275).  
 
 
 
 
Table 1 Subject 
characteristics and 
indoleamine 2, 3-
dioxygenase (IDO) 
levels. Variables  
Seropositive leprosy  
(n=29)  
Seronegative leprosy  
(n =30)  
P  
Sex  
Male (%)  
Female (%)  
20.7  
79.3  
33.3  
66.7  
0.275a  
 
Level of education  
Primary education (%)  
Higher education (%)  
82.8  
17.2  
80.0  
20.0  
0.786a  
 
Age (years), (mean + 
SD)  
 
 
3 ± 10  
 
35 ± 11  
 
0.399b  
IDO (pg/mL), (median 
+ SD) 
  
a=chi-square test, b= 
independent t-test, 
c=Mann-Whitney test 
 
13.80 ± 9.13  9.10 ± 4.60  0.048c  
In level of education variable, seropositive leprosy subjects in primary education is 
82.8% and 17.2% is in higher  
education while in (RR) patients. LL lesions were characterized by Seronegative leprosy 
subjects there were 80% in primary education and 20% in higher education (p = 0.786)  
The mean age of seropositive leprosy subjects was 33±10 years and the mean age of 
seronegative leprosy subjects was 35±11 years. (p = 0.399)  
The mean IDO level in seropositive leprosy subject was 13.80±9.13 pg/mL while that in 
seronegative leprosy subject was 9.10±4.60 pg/mL. There was significant difference 
between seropositive leprosy and seronegative leprosy subjects in terms of IDO level 
(p=0.048).  
 
Discussion  
The first body mechanical defense against Mycobacterium leprae is by activating the 
antigen presenting cells (APCs) of immune system, i.e. the dendritic cells, monocytes and 
macrophages. IDO is predominantly expressed in APCs. Interferon gamma (IFN-γȌ and 
dependent and/or independent signal pathways can activate and mediate IDO.7  
Higher level of IDO found in seropositive leprosy subjects of our study supported the 
results of previous studies which indicate a high IDO protein expression in lepromatous 
skin lesions and high IDO activity in the sera of lepromatous leprosy patients.5 People 
who live together under one and the same roof with leprosy patients with seropositive 
anti-PGL-I antibody have higher risk for developing leprosy (particularly the 
lepromatous type) compared to those who have contact with seronegative patients. The 
anti-PGL-I antibody level in people who live together under one and the same roof with 
leprosy indicates increased risk of having leprosy in the next 4 years. Another study in 
Philippines showed an increased risk of developing leprosy to 24-fold is caused by 
seropositive contacts.8,9  
In addition due to M. leprae, the increased IDO activity in the sera of lepromatous leprosy 
patients also depends on IFN-γ. There is also a statement that )DO activity was at least 
partially dependent upon IFN-γ from a study in dengue patients.ͳͲ )DO can be induced 
in response to various stimuli. The most potent inducer is IFN- γ, although other 
inflammatory stimuli, including type-I interferons (IFN-Ƚ/ȾȌ and bacterial 
lipopolysaccharide (LPS), and some viruses and intracellular pathogens, can induce IDO expression.ͳ5 Support for the ǲtwo signalǳ requirement for )DO-expression has also been 
obtained in human samples.14 For example, human monocytes expressed IDO in 
lepromatous leprosy due to the synergistic actions of IFN-γ and the bacterium ȋlikely 
through pattern recognition receptor signaling).5 M. leprae and IFN-γ is a cause of an 
increased of IDO expression in monocytes leprosy patients lepromatous type.5 Leprosy 
patients with clinical manifestation of leprosy or those with seronegative leprosy have a 
less IFN-γ level than seropositive leprosy.ͳͳ  
A higher IDO level in seropositive group found in our study supports the results of some 
previous studies, which showed that IDO induction after bacterial infection could be 
beneficial to the host. Amino acid tryptophan will break into stable metabolite called 
kynurenine when the IDO level increases.12 Moreover, tryptophan depletion and 
starvation will occur since bacteria need tryptophan.13,14 The growth of bacteria is 
dependent on the greater amount of tryptophan rather than T cells.13  
IDO could be considered to be a double-edged sword in the immune response against 
pathogens. Immune cells, including antigen-presenting cells like DCs, are able to express 
IDO in response to various stimuli.10  
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